FibroBiologics Common StockNASDAQ: FBLG

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 February 2024

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$80.76 M
-91%vs. 3y high
42%vs. sector
-vs. 3y high
-vs. sector
-96%vs. 3y high
98%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 22:17:24 GMT
$2.33-$0.17(-6.99%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

FBLG Latest News

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
globenewswire.com19 November 2024 Sentiment: POSITIVE

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach.

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
globenewswire.com14 November 2024 Sentiment: POSITIVE

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor (TF)-expressing cells to prevent IBMIR-mediated blood clotting.

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
globenewswire.com29 October 2024 Sentiment: POSITIVE

HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced promising new findings from its artificial thymus organoid program. Recent results from the artificial thymus organoid program showed that fibroblasts and thymus-derived cell organoids can persist and function for over 50 days post-transplantation, with vascularization and the generation of a diverse array of mature T cells in animal models.

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
globenewswire.com18 October 2024 Sentiment: POSITIVE

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testing, and manufacturing solutions provider established a master services agreement to develop and manufacture FibroBiologics' therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for utilization in a diabetic foot ulcer (DFU) clinical trial slated to begin in 2025.

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
globenewswire.com16 October 2024 Sentiment: POSITIVE

HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the issuance of a patent from the European Patent Office (Patent Number 19795975.2) covering methods and compositions for the treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual.

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
globenewswire.com11 October 2024 Sentiment: POSITIVE

HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Pete O'Heeron, Chief Executive Officer of FibroBiologics, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 10:00 a.m. ET.

FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
globenewswire.com30 September 2024 Sentiment: POSITIVE

Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs

FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
globenewswire.com12 September 2024 Sentiment: POSITIVE

HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional hemopoietic organoids that can give rise to immune cells.

FibroBiologics Files 2024 Second Quarter Report
globenewswire.com07 August 2024 Sentiment: POSITIVE

HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission.

FibroBiologics to Present at JonesTrading Healthcare Summit 2024
globenewswire.com15 July 2024 Sentiment: POSITIVE

HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the JonesTrading Healthcare Seaside Summit occurring July 14-16, 2024, in San Diego, California.

What type of business is FibroBiologics Common Stock?

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

What sector is FibroBiologics Common Stock in?

FibroBiologics Common Stock is in the Healthcare sector

What industry is FibroBiologics Common Stock in?

FibroBiologics Common Stock is in the Biotechnology industry

What country is FibroBiologics Common Stock from?

FibroBiologics Common Stock is headquartered in United States

When did FibroBiologics Common Stock go public?

FibroBiologics Common Stock initial public offering (IPO) was on 01 February 2024

What is FibroBiologics Common Stock website?

https://www.fibrobiologics.com

Is FibroBiologics Common Stock in the S&P 500?

No, FibroBiologics Common Stock is not included in the S&P 500 index

Is FibroBiologics Common Stock in the NASDAQ 100?

No, FibroBiologics Common Stock is not included in the NASDAQ 100 index

Is FibroBiologics Common Stock in the Dow Jones?

No, FibroBiologics Common Stock is not included in the Dow Jones index

When was FibroBiologics Common Stock the previous earnings report?

No data

When does FibroBiologics Common Stock earnings report?

The next expected earnings date for FibroBiologics Common Stock is 28 February 2025